Elina Toskala, MD
Otolaryngic Allergy · Philadelphia, PANPI 1639517063
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by GSK at 43.0% of the total. 2025 is the largest year on record at $44,373, more than ten times the $1,615 reported in 2019.
Across 180 payments — averaging $597.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$46K
- Sanofi$18K
- Medtronic$14K
- Aerin Medical Inc.$12K
- Regeneron Healthcare Solutions, Inc.$10K
- AstraZeneca$3K
- plus $4K from 12 others
Across 23 payments — averaging $4719.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$82K
- Aerin Medical Inc.$26K
- Sanofi$750
What the payments were for
- Consulting fees$35,39833%
- Speaking & faculty fees$54,21750%
- Travel & lodging$10,0789%
- Food & beverage$7,8787%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 53 | $46,218 |
| Sanofi | 16 | $18,236 |
| Medtronic(2 entities) | 30 | $14,071 |
| Aerin Medical Inc. | 27 | $11,988 |
| Regeneron Healthcare Solutions, Inc. | 9 | $10,384 |
| AstraZeneca | 1 | $2,551 |
| Fiagon NA LLC | 1 | $1,500 |
| Intersect ENT, Inc. | 6 | $628 |
| Integra Lifesciences Corporation | 6 | $592 |
| Stryker | 10 | $514 |
| Acclarent, Inc | 9 | $459 |
| Optinose US, Inc. | 5 | $205 |
| Neurent Medical Limited | 1 | $84 |
| Sanofi-aventis U.S. LLC | 1 | $38 |
| Regeneron | 1 | $34 |
| Phadia US Inc. | 2 | $30 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$34,129
- NUCALA$33,130
- VIVAER STYLUS$11,187
- PROPEL$8,079
- RHINAER STYLUS$4,409
- STRAIGHTSHOT$950
- Acclarent Aera$541
- Inspira Air$541
- RELIEVA SPINPLUS NAV$541
- TruDi Probe$541
- StealthStation$473
- Navigation CUBE$299
- SCOPIS ENT$281
- NUVENT$250
- Acclarent Navwire$145
- WAYRILZ$144
- STEALTHSTATION S8 PLATFORM$129
- Xhance$106
How this compares
Too few otolaryngic allergy providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 18 | $66,548 |
| Dupixent SyringeDupilumab | 12 | $44,368 |
| NucalaMepolizumab | 11 | $41,386 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $21,645 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $21,078 |
| Azelastine Hcl | 448 | $9,302 |
| Fluticasone Propionate | 324 | $4,153 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $3,666 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $3,088 |
| Ipratropium Bromide | 108 | $3,026 |
| Epinephrine | 14 | $3,003 |
| Famotidine | 150 | $2,649 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 12 | $1,462 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $1,106 |
| Omeprazole | 99 | $1,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $46,218 | $84,10982 claims |
| AstraZenecaSymbicort | $2,551 | $3,66617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few otolaryngic allergy providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.
Other otolaryngic allergy in Philadelphia
- Zaher SrourHanover$4K
- Alexander KeszeliExton$3K
- Mohammad AkbarPottsville$2K
- Louis MariottiKingston$1K
- Sidney LipmanErie$958
- Jack AnonErie$642
- Allison HarbartJohnstown$280
- David RogersonJohnstown$80
- Kristin BrantJohnstown$15
- David ArmstrongJohnstown$13
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.